Novel anti-arrhythmic drugs for atrial fibrillation management

Current Vascular Pharmacology

Volumn 5, Issue 3, 2007, Pages 185-194

  Ehrlich, Joachim R ^a   Nattel, Stanley ^b   H Hohnloser, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Atrial fibrillation; HERG; Pharmacotherapy; Proarrhythmia; Ventricular fibrillation

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; 2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 2' (BENZYLOXYCARBONYLAMINOMETHYL) BIPHENYL 2 CARBOXYLIC ACID 2 (2 PYRIDYL)ETHYLAMIDE; 2' [[2 (4 METHOXYPHENYL) ACETYLAMINO] METHYL] BIPHENYL 2 CARBOXYLIC ACID 2,4 DIFLUORO BENZYLAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 4 CYCLOPROPYLAMINO 3,4 DIHYDRO 2,2 DIMETHYL 6 (4 METHOXYPHENYLACETYLAMINO) 7 NITRO 2H 1 BENZOPYRAN 3 OL; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; C 9356; CANDESARTAN; CARBACHOL; CARDIOVASCULAR AGENT; CORREOLIDE; DIPHENYLPHOSPHINE OXIDE 1; GAP JUNCTION PROTEIN; IBUTILIDE; IRBESARTAN; LORATADINE; LOSARTAN; NIP 141; NIP 142; PLACEBO; PROPAFENONE; ROTIGAPTIDE; S 20951; S 9947; TERTIAPIN Q; UNCLASSIFIED DRUG; VERNAKALANT; ZATEBRADINE; NEW DRUG; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TARGETING; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IC 50; LOADING DRUG DOSE; NONHUMAN; PROTEIN EXPRESSION; QT PROLONGATION; REVIEW; TACHYCARDIA; ANIMAL; CELL JUNCTION; DRUG EFFECT; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CONNEXINS; DRUGS, INVESTIGATIONAL; GAP JUNCTIONS; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIUM; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 34547596545     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107781024073     Document Type: Review

References (90)

1. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006; 367: 262-272.
2. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, felcainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781-788.
3. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized trials. Circulation 1990; 82: 1106-1116.
4. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
5. Pedersen OD, Bagger H, Keller N, Marhcant B, Kober L, Torp-Pedersen C. Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients with Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 2001; 104: 292-296.
6. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
7. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995; 6: 920-936.
8. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
9. Li D, Benardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000; 102: 104-112.
10. Suttorp MJ, Kingma JH, Lie AH, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63: 693-696.
11. Daoud EG, Hummel JD, Augostini R, Williams S, Kalbfliesch SJ. Effect of verapamil on immediate recurrence of atrial fibrillation. J Cardiovasc Electrophysiol 2000; 11: 1231-1237.
12. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001; 49: 762-770.
13. Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 1998; 351: 1829-1830.
14. + channel proteins Kir3.1 and Kir3.4 in the ventricle, atrium, and sinoatrial node of heart. J Histochem Cytochem 2001; 49: 1221-1234.
15. Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001; 103: 684-690.
16. Dobrev D, Graf E, Wettwer E, Himmel HM, Hala O, Doerfel C, et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 2001; 104: 2551-2557.
17. Ehrlich JR, Cha TJ, Zhang L, Chartier D, Villeneuve L, Herbert TE, et al. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol 2004; 557: 583-597.
18. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005; 112: 3697-3706.
19. Cha TJ, Ehrlich JR, Chartier D, Qi XY, Xiao L, Nattle S. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006; 113: 1730-1737.
20. + channels. Biochemistry 1998; 37: 13291-13299.
21. + channels. Biochemistry 1999; 38: 14286-14293.
22. Hashimoto N, Yamashita T, Tsuruzoe N. Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 2006; 54: 136-141.
23. + channels in a use-dependent manner. J Pharmacol Exp Ther 2005; 314: 1353-1361.
24. Dudkin SM, Mikchaylova LI, Severin ES, Jr. Mechanisms of cyclic AMP phosphodiesterase regulation. Adv Enzyme Regul 1983; 21: 333-352.
25. + channel Kv1.5 current. Life Sci 2001; 68: 2017-2024.
26. Matsuda T, Takeda K, Ito M, Ygmagishi R, Tamura M, Nakamura H, et al. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractoty period and action potential duration in guinea pig myocardium. J Pharmacol Sci 2005; 98: 33-40.
27. Nagasawa H, Fujiki A, Fujikura N, Matsuda T, Yamashita T, Inoue H. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ J 2002; 66: 185-191.
28. Seki A, Hagiwara N, Kasanuki H. Effects of NIP-141 on K currents in human atrial myocytes. J Cardiovasc Pharmacol 2002; 39: 29-38.
29. Gogelein H, Brendel J, Steinmeyer K, Strubing C, Picard N, Rampe D, et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 183-192.
30. Decher N, Kumar P, Gonzalez T, Pirard B, Sanquinetti MC. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol 2006; 70: 1204-1211.
31. Ehrlich JR, Hoche C, Coutu P, Metz-Weidmann C, Dittrich W, Hohnloser SH, et al. Properties of a Time-dependent Potassium Current in Pig Atrium - Evidence for a Role of Kv1.5 in Repolarization. J Pharmacol Exp Ther 2006; 319: 898-906.
32. Wettwer E, Hala O, Christ T, Heubach JF, Doprev D, Knaut M, et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004; 110: 2299-2306.
33. Courtemanche M, Ramirez RJ, Nattel S. Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol 1998; 275: H301-H321.
34. de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, et al. AVE0118, Blocker of the Transient Outward Current (Ito) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat. Circulation 2006; 114: 1234-1242.
35. Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, et al. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res 2003; 60: 298-306.
36. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004; 110: 1717-1724.
37. Nakaya H, Furusawa Y, Ogura T, Tamagawa M, Uemura H. Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts. Br J Pharmacol 2000; 131: 1363-1372.
38. Kumagai K, Nakashima H, Gondo N, Saku K. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol 2003; 14: 880-884.
39. Kimura J, Kawahara M, Sakai E, Yatabe J, Nakanishi H. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol 1999; 79: 275-281.
40. + current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 646-653.
41. + current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061-1076.
42. + channel protein in explanted cardiac tissue. J Clin Invest 1995; 96: 282-292.
43. Nattel S, Yue L, Wang Z. Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity. Cell Physiol Biochem 1999; 9: 217-226.
44. Yue L, Wang Z, Rindt H, Nattel S. Molecular evidence for a role of Shaw (Kv3) potassium channel subunits in potassium currents of dog atrium. J Physiol 2000; 527 Pt 3: 467-478.
45. + current in canine atrial myocytes. Circ Res 2003; 93: 744-751.
46. + current densities and Kv1.5 expression are reduced in chronic atrial fibrillation. Circ Res 1997; 80: 772-781.
47. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44: 121-131.
48. Workman AJ, Kane KA, Rankin AC. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res 2001; 52: 226-235.
49. 2+-channel, beta-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res Cardiol 2001; 96: 82-90.
50. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004; 15: 1444-1450.
51. Persson F, Carlsson L, Duker G, Phd IJ. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol 2005; 46: 7-17.
52. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD70009. J Cardiovasc Electrophysiol 2005; 16: 329-341.
53. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol 2006; 47: 123-132.
54. Lofberg L, Jacobson I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace 2006; 8: 549-557.
55. + currents in the heart. Am J Physiol Heart Circ Physiol 2003; 285: H1641-H1649.
56. + channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther 2006; 317: 1054-1063.
57. Stump GL, Wallace AA, Regan CP, Lynch JJ Jr. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 2005; 315: 1362-1367.
58. Regan CP, Wallace AA, Cresswell HK, Lynch JJ Jr. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Ther 2006; 316: 727-732.
59. Bachmann A, Gutcher I, Kopp K, Brendel J, Bosch RF, Busch AE, et al. Characterization of a novel Kv1.5 channel blocker in Xenopus occytes, CHO cells, human and rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 472-478.
60. Knobloch K, Brendel J, Peukert S, Rosenstein B, Busch AE, Wirth KJ. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 482-487.
61. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005; 16: 1227-1238.
62. Fedida D, Orth PM, Hesketh JC, Ezrin AM. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol 2006; 17 Suppl 1: S71-S78.
63. Orth PM, Hesketh JC, Mak CK, Yang Y, Lin S, Beatch GN, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006; 70: 486-496.
64. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004; 44: 2355-2361.
65. Götz MA, Hensens OD, Zink DL, Borris RP, Morales F, Tamayo-Castillo G, et al. Tetrahedron Lett 1998; 39: 2895-2898.
66. Felix JP, Bugianesi RM, Schmalhofer WA, Borris R, Goetz MA, Hensens OD, et al. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 1999; 38: 4922-4930.
67. + channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 2004; 95: 308-318.
68. Valenzuela C, Delpon E, Franqueza L, Gay P, Perez O, Tamargo J, et al. Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels. Circulation 1996; 94: 562-570.
69. Delpon E, Valenzuela C, Gay P, Franqueza L, Synders DJ, Tamargo J. Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 1997; 35: 341-350.
70. Moreno I, Caballero R, Gonzalez T, Arias C, Valenzuela C, Iriepa I, et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003; 304: 862-873.
71. + currents. Circulation 2000; 101: 1199-1205.
72. Caballero R, Delpon E, Valenzuela C, Longobardo M, Gonzalez T, Tamargo J. Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization. Mol Pharmacol 2001; 59: 825-836.
73. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27: 512-518.
74. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
75. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336.
76. Saffitz JE, Schuessler RB, Yamada KA. Mechanisms of remodeling of gap junction distributions and the development of anatomic substrates of arrhythmias. Cardiovasc Res 1999; 42: 309-317.
77. Hagendorff A, Schumacher B, Kirchhoff S, Luderitz B, Willecke K. Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 1999; 99: 1508-1515.
78. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001; 38: 883-891.
79. Wilhelm M, Kirste W, Kuly S, Amann K, Neuhuber W, Weyand M, et al. Atrial distribution of connexin 40 and 43 in patients with intermittent, persistent, and postoperative atrial fibrillation. Heart Lung Circ 2006; 15: 30-37.
80. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-379.
81. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006; 354: 2677-2688.
82. Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation 2003; 108: 3157-3163.
83. Aonuma S, Kohama Y, Makino T, Fujisawa Y. Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J Pharmacobiodyn 1982; 5: 40-48.
84. Xing D, Kjolbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou NH, et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 2003; 14: 510-520.
85. Haugan K, Miyamoto T, Takeishi Y, Kubota I, Nakayama J, Shimojo H, et al. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmacol Toxicol 2006; 99: 71-79.
86. Guerra JM, Everett TH, Lee KW, Wilson E, Olgin JE. Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation. Circulation 2006; 114: 110-118.
87. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003; 107: 1930-1936.
88. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Circulation 2006; in revision:
89. Matsuda T, Ito M, Ishimaru S, Tsuruoka N, Saito T, Iida-Tanaka N, et al. Blockade by NIP-142, an Antiarrhythmic Agent, of Carbachol-Induced Atrial Action Potential Shortening and GIRK1/4 Channel. J Pharmacol Sci 2006; 101: 303-310.
90. Drici MD, Diochot S, Terrenoire C, Romey G, Lazdunski M. The bee venom peptide tertiapin underlines the role of I(KACh) in acetylcholine-induced atrioventricular blocks. Br J Pharmacol 2000; 131: 569-577.